JP2004520435A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520435A5 JP2004520435A5 JP2002571486A JP2002571486A JP2004520435A5 JP 2004520435 A5 JP2004520435 A5 JP 2004520435A5 JP 2002571486 A JP2002571486 A JP 2002571486A JP 2002571486 A JP2002571486 A JP 2002571486A JP 2004520435 A5 JP2004520435 A5 JP 2004520435A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- ring
- independently selected
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003118 aryl group Chemical group 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010011953 Decreased activity Diseases 0.000 claims 1
- 206010052402 Gastrointestinal hypermotility Diseases 0.000 claims 1
- 206010052105 Gastrointestinal hypomotility Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 230000008369 airway response Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- RBNPZEHAODHBPZ-UHFFFAOYSA-M dihydroxyaluminium Chemical compound O.O.NCC(=O)O[Al] RBNPZEHAODHBPZ-UHFFFAOYSA-M 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27541701P | 2001-03-13 | 2001-03-13 | |
| PCT/US2002/007106 WO2002072570A2 (en) | 2001-03-13 | 2002-03-11 | Non-imidazole compounds as histamine h3 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004520435A JP2004520435A (ja) | 2004-07-08 |
| JP2004520435A5 true JP2004520435A5 (enExample) | 2005-12-22 |
| JP4522651B2 JP4522651B2 (ja) | 2010-08-11 |
Family
ID=23052201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002571486A Expired - Fee Related JP4522651B2 (ja) | 2001-03-13 | 2002-03-11 | 新規非イミダゾール化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6849621B2 (enExample) |
| EP (1) | EP1373251A2 (enExample) |
| JP (1) | JP4522651B2 (enExample) |
| CN (1) | CN1298715C (enExample) |
| AR (1) | AR035440A1 (enExample) |
| AU (1) | AU2002244271A1 (enExample) |
| CA (1) | CA2440559C (enExample) |
| MX (1) | MXPA03008356A (enExample) |
| MY (1) | MY131890A (enExample) |
| WO (1) | WO2002072570A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| US20030191110A1 (en) * | 2001-11-01 | 2003-10-09 | Martyn Botfield | Modulators of the cholesterol biosynthetic pathway |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| CN100360130C (zh) | 2002-04-18 | 2008-01-09 | 先灵公司 | 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮 |
| MY135686A (en) * | 2002-06-24 | 2008-06-30 | Schering Corp | Indole derivatives useful as histamine h3 antagonists |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| HRP20080541T3 (en) | 2003-04-23 | 2008-12-31 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| WO2007030148A2 (en) * | 2005-04-15 | 2007-03-15 | S. C. Johnson & Son, Inc. | Continuous adhesive twin roller cleaning device |
| US20060276464A1 (en) * | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| EP1888527A1 (en) * | 2005-05-27 | 2008-02-20 | AstraZeneca AB | Piperidines for the treatment of chemokine mediated diseases |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| DE602006010870D1 (de) * | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| CA2609957A1 (en) * | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| CA2615650A1 (en) | 2005-07-21 | 2007-01-25 | Astrazeneca Ab | Novel piperidine derivatives |
| WO2007035703A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| AU2006331850A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine H3 antagonists |
| CA2634235A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| JP2009521448A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| CA2634940A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| AU2007231594A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
| AU2008335135A1 (en) | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| US8080566B1 (en) | 2008-06-11 | 2011-12-20 | Kalypsys, Inc | Carbazole inhibitors of histamine receptors for the treatment of disease |
| EP2318388A2 (en) | 2008-07-23 | 2011-05-11 | Schering Corporation | Tricyclic spirocycle derivatives and methods of use thereof |
| CA2739491A1 (en) | 2008-10-16 | 2010-04-22 | Schering Corporation | Azine derivatives and methods of use thereof |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| WO2010071822A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Piperidine and piperazine derivatives and methods of use thereof |
| JP5677325B2 (ja) * | 2010-01-22 | 2015-02-25 | 大鵬薬品工業株式会社 | Ｐｇｄｓ阻害作用を有するピペラジン化合物 |
| TW201321353A (zh) | 2011-10-08 | 2013-06-01 | Novartis Ag | 胺基甲酸酯／尿素衍生物 |
| US9034874B2 (en) | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
| US11203582B2 (en) * | 2017-06-15 | 2021-12-21 | The Board Of Regents Of The University Of Oklahoma | Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress |
| US11318144B2 (en) | 2019-04-12 | 2022-05-03 | LA PharmaTech Inc. | Compositions and methods for treating Alzheimer's disease and Parkinson's disease |
| US10966989B2 (en) | 2019-04-12 | 2021-04-06 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders |
| US10639315B1 (en) | 2019-05-21 | 2020-05-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating Alzheimer's disease |
| US11690849B2 (en) | 2019-04-12 | 2023-07-04 | LA PharmaTech Inc. | Method of treating dementia |
| US10898493B2 (en) | 2019-04-12 | 2021-01-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease |
| WO2020222799A1 (en) * | 2019-04-30 | 2020-11-05 | La Pharma Tech Inc. | A method of treating mental, behavioral, cognitive disorders |
| US11744833B2 (en) | 2019-04-12 | 2023-09-05 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of insomnia |
| US11938139B2 (en) | 2019-04-12 | 2024-03-26 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders |
| US10639314B1 (en) | 2019-04-30 | 2020-05-05 | LA PharmaTech Inc. | Method of treating Alzheimer's disease |
| US11389458B2 (en) | 2019-04-12 | 2022-07-19 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treating parkinson's and huntington's disease |
| EP3973586A4 (en) * | 2019-05-21 | 2023-01-11 | La Pharma Tech Inc. | NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS |
| US11351179B1 (en) | 2021-08-05 | 2022-06-07 | LA PharmaTech Inc. | Pharmaceutical compositions and methods for treatment of psychiatric disorders |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624734A (en) * | 1950-04-29 | 1953-01-06 | Hoffmann La Roche | Bipiperidine derivatives |
| NL131191C (enExample) * | 1964-06-17 | |||
| US3401224A (en) * | 1965-06-14 | 1968-09-10 | Barrett Paul Anthony | Treatment of depression with nu-benzylpiperazine |
| NL129629C (enExample) * | 1965-07-02 | |||
| JPS5612359A (en) | 1979-07-10 | 1981-02-06 | Mitsui Petrochem Ind Ltd | Preparation of tetra-substituted urea derivative |
| GR81827B (enExample) * | 1983-03-21 | 1984-12-12 | Boehringer Ingelheim Ltd | |
| US4725597A (en) * | 1983-03-21 | 1988-02-16 | Boehringer Ingelheim Ltd. | Bis(piperazinyl or homopiperazinyl)alkanes |
| AU6062590A (en) | 1989-07-07 | 1991-02-06 | Schering Corporation | Pharmaceutically active compounds |
| DE69212844T2 (de) | 1991-12-18 | 1997-01-09 | Schering Corp., Kenilworth, N.J. | Imidazolyl oder imidazolylalkyl substituiert mit einem 4- oder 5-gliedrigen stickstoff enthaltenden heterozyklischen ring |
| US5633250A (en) | 1991-12-18 | 1997-05-27 | Schering Corporation | Imidazoylalkyl substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
| US5807872A (en) | 1992-12-16 | 1998-09-15 | Schering Corporation | Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring |
| NZ276883A (en) | 1993-11-15 | 1998-08-26 | Schering Corp | 1h-imidazol-4-yl)alkyl]benzene derivatives |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| MY116130A (en) | 1996-08-16 | 2003-11-28 | Schering Corp | Treatment of upper airway allergic responses |
| US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
| US6034251A (en) | 1997-11-07 | 2000-03-07 | Schering Corporation | Phenyl-alkyl-imidazoles |
| NZ504124A (en) | 1997-11-07 | 2002-10-25 | Schering Corp | Phenyl-alkyl-imidazoles and use in treating inflammatory disease |
| US5990147A (en) | 1997-11-07 | 1999-11-23 | Schering Corporation | H3 receptor ligands of the phenyl-alkyl-imidazoles type |
| DE69937045T2 (de) * | 1998-02-19 | 2008-05-29 | Kowa Co., Ltd., Nagoya | Cyclische amidderivate |
| WO2000000488A1 (en) | 1998-06-30 | 2000-01-06 | Schering Corporation | Muscarinic antagonists |
| US6100279A (en) | 1998-11-05 | 2000-08-08 | Schering Corporation | Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom |
| ATE261941T1 (de) * | 1998-12-24 | 2004-04-15 | Lilly Co Eli | Heterocyclische amide als inhibitoren von faktor xa |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| CA2436083A1 (en) * | 2001-02-08 | 2002-09-19 | Schering Corporation | Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders |
-
2002
- 2002-03-11 JP JP2002571486A patent/JP4522651B2/ja not_active Expired - Fee Related
- 2002-03-11 CN CNB028065611A patent/CN1298715C/zh not_active Expired - Fee Related
- 2002-03-11 US US10/095,134 patent/US6849621B2/en not_active Expired - Fee Related
- 2002-03-11 EP EP02709808A patent/EP1373251A2/en not_active Withdrawn
- 2002-03-11 MX MXPA03008356A patent/MXPA03008356A/es active IP Right Grant
- 2002-03-11 WO PCT/US2002/007106 patent/WO2002072570A2/en not_active Ceased
- 2002-03-11 CA CA2440559A patent/CA2440559C/en not_active Expired - Fee Related
- 2002-03-11 MY MYPI20020872A patent/MY131890A/en unknown
- 2002-03-11 AU AU2002244271A patent/AU2002244271A1/en not_active Abandoned
- 2002-03-12 AR ARP020100884A patent/AR035440A1/es unknown
-
2004
- 2004-10-27 US US10/974,329 patent/US7238688B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2564201A1 (en) | Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands | |
| JP3664492B2 (ja) | タチキニン ｎｋ▲下３▼ 受容体アンタゴニストとしてのキノリン誘導体 | |
| TWI268928B (en) | Novel quinoline compounds, the processes for their preparation, the compositions containing them and their uses as medicaments | |
| ES2651615T3 (es) | Amidoderivado y medicamento | |
| HUP0401876A2 (hu) | Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| SE0104332D0 (sv) | Therapeutic agents | |
| AR035440A1 (es) | Compuestos antagonistas del receptor h3, el uso de los mismos solos o en combinacion para la manufactura de medicamentos y composiciones farmaceuticas | |
| JP6048409B2 (ja) | グアニジノ安息香酸化合物 | |
| RU2005119281A (ru) | Диазинопиримидины | |
| JPH10279578A5 (enExample) | ||
| JP2010509286A5 (enExample) | ||
| RU2002123350A (ru) | Дипептиднитрильные ингибиторы катепсина К | |
| ES2277098T3 (es) | Derivados de quinolina y aza-indol y su uso como ligandos para 5-ht6. | |
| CY1110500T1 (el) | Νεα φαρμακα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας | |
| RU2003114748A (ru) | Новые соединения, не являющиеся имидазолами | |
| JP2006514626A5 (enExample) | ||
| PT2248807E (pt) | Derivados de n-fenil-2-pirimidina-amina | |
| JP2000512614A (ja) | Ｎｋ３アンタゴニストとしてのキノリン誘導体 | |
| JP2008050365A5 (enExample) | ||
| JP2004532240A5 (enExample) | ||
| JP2004532240A (ja) | ５−ｈｔ６受容体アンタゴニストとしてのベンゾ［ｄ］アゼピン誘導体 | |
| JP2007505075A (ja) | キノリン化合物およびそれを含む医薬組成物 | |
| JP2007538031A5 (enExample) | ||
| JP2006519812A (ja) | フェニルスルホン誘導体およびｃｎｓ障害の治療におけるその使用 | |
| US5017703A (en) | Indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same |